Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
A strong vaccine-induced T cell response during standard-of-care chemotherapy correlates with survival in patients with advanced cervical cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-5-678_2 · Cited by 1,471
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Self-citationCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 727
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709 · cited 1×
“In general, the immune system of patients with late-stage cancer is compromised to such an extent that vaccine monotherapy generally fails (28).”
BackgroundSelf-citationMonk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8909 · Cited by 693
Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31607-0 · Cited by 684 · cited 1×
“1 months, high and low HPV vaccine responders combined, and was close to the outcome of the study in which a mixed population of patients with advanced metastatic and recurrent cervical cancer was treated first line with the combination of chemotherapy and bevacizumab (39, 40).”
ResultDirect Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503 · cited 11×
“This was tried because IFN is a strong promoter of cross-presentation of proteins by dendritic cells (DCs) (19) and is responsible for the up-regulation of costimulatory molecule expression and costimulatory cytokine production by DCs (20) and also promotes more efficient processing and presentation of long peptides (…”
BackgroundMethodInfluentialMassarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490
Self-citationPiersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414
Self-citationKitagawa, R., Katsumata, N., Shibata, T., Kamura, T., Kasamatsu, T., Nakanishi, T., Nishimura, S., Ushijima, K., Takano, M., Satoh, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4391 · Cited by 389
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Self-citationWelters, M. J. P., Kenter, G. G., Piersma, S. J., Vloon, A. P. G., Löwik, M. J. G., Berends-van der Meer, D. M. A., Drijfhout, J. W., Valentijn, A. R. P. M., Wafelman, A. R., Oostendorp, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1880 · Cited by 373
Self-citationTumor-induced perturbations of cytokines and immune cell networks
Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.004 · Cited by 356
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 315
Self-citationde Jong, A., van Poelgeest, M. I. E., van der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J. M., Kenter, G., Offringa, R., & van der Burg, S. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0831 · Cited by 309 · cited 1×
“Studies in healthy individuals and patients have assigned a major role for HPV16 E6/E7 oncoproteinspecific type 1 T cell immunity in the protection against progressive premalignant disease and a better response to standard therapy at the stage of cancer (7, 8).”
BackgroundSelf-citationImmunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282
Welters, M. J. P., Kenter, G. G., de Vos van Steenwijk, P. J., Löwik, M. J. G., Berends-van der Meer, D. M. A., Essahsah, F., Stynenbosch, L. F. M., Vloon, A. P. G., Ramwadhdoebe, T. H., Piersma, S. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006500107 · Cited by 239
Self-citationJordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Kenter, G. G., van der Burg, S. H., & Fleuren, G. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4554 · Cited by 233
Self-citationvan der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M. C., van den Hende, M., Welters, M. J. P., Van Rood, J. J., Fleuren, G. J., Melief, C. J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704672104 · Cited by 217
Self-citationVaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Welters, M. J., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., Santegoets, S. J., Arens, R., de Kam, M. L., Cohen, A. F., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8307 · Cited by 216
Self-citationSantegoets, S. J. A. M., Dijkgraaf, E. M., Battaglia, A., Beckhove, P., Britten, C. M., Gallimore, A., Godkin, A., Gouttefangeas, C., de Gruijl, T. D., Koenen, H. J. P. M., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1729-x · Cited by 211
Self-citationLorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F., & Barni, S. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.042 · Cited by 207
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Persijn van Meerten, E. L., van den Hende, M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Fathers, L. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-88 · Cited by 193
Self-citationvan Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2594 · Cited by 167
Self-citationWelters, M. J. P., Ma, W., Santegoets, S. J. A. M., Goedemans, R., Ehsan, I., Jordanova, E. S., van Ham, V. J., van Unen, V., Koning, F., van Egmond, S. I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2140 · Cited by 167
Self-citationSpadaro, F., Lapenta, C., Donati, S., Abalsamo, L., Barnaba, V., Belardelli, F., Santini, S. M., & Ferrantini, M. (2012) · Blood · doi:10.1182/blood-2011-06-363564 · Cited by 149
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Beyranvand Nejad, E., van der Sluis, T. C., van Duikeren, S., Yagita, H., Janssen, G. M., van Veelen, P. A., Melief, C. J. M., van der Burg, S. H., & Arens, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0881 · Cited by 136
Self-citationvan der Sluis, T. C., van Duikeren, S., Huppelschoten, S., Jordanova, E. S., Beyranvand Nejad, E., Sloots, A., Boon, L., Smit, V. T. H. B. M., Welters, M. J. P., Ossendorp, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2142 · Cited by 89
Self-citationCho, Y., Kim, K. H., Yoon, H. I., Kim, G. E., & Kim, Y. B. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw308 · Cited by 69
Zeestraten, E. C. M., Speetjens, F. M., Welters, M. J. P., Saadatmand, S., Stynenbosch, L. F. M., Jongen, R., Kapiteijn, E., Gelderblom, H., Nijman, H. W., Valentijn, A. R. P. M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27819 · Cited by 61
Self-citationThe Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival
Santegoets, S. J. A. M., van Ham, V. J., Ehsan, I., Charoentong, P., Duurland, C. L., van Unen, V., Höllt, T., van der Velden, L., van Egmond, S. L., Kortekaas, K. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1749 · Cited by 61
Self-citationNivolumab for Squamous-Cell Cancer of Head and Neck
González-Rodríguez, E., Rodríguez‐Abreu, D., & Boronat, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1615565 · Cited by 43 · cited 1×
“Patients treated with this combination had about twice the overall response rate and twice the median survival time compared to those treated in the registration study of nivolumab monotherapy for this disease indication (35).”
Resultvan Steenwijk, P. J. D. V., Piersma, S. J., Welters, M. J. P., van der Hulst, J. M., Fleuren, G. J., Hellebrekers, B. W. J., Kenter, G. G., & van der Burg, S. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0994 · Cited by 42
Self-citationSantegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. C., van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465166 · Cited by 42
Self-citationSingh, S., Meyering, M., Ramwadhdoebé, T. H., Stynenbosch, L. F. M., Redeker, A., Kuppen, P. J. K., Melief, C. J. M., Welters, M. J. P., & van der Burg, S. H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1251-3 · Cited by 32
Self-citationGouw, Z. A. R., de Boer, J. P., Navran, A., van den Brekel, M. W. M., Sonke, J., & Al‐Mamgani, A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.02.003 · Cited by 25 · cited 1×
“To obtain this effect, carboplatin/paclitaxel may be used in the treatment of several types of cancer because cancer- related leukocytosis is commonly observed in patients with immunogenic tumors (29, 30).”
BackgroundRyu, K. S., Lee, Y. S., Kim, B. K., Park, Y. G., Kim, Y. W., Hur, S. Y., Kim, T. E., Kim, I.-K., & Kim, J. W. (2001) · Experimental & Molecular Medicine · doi:10.1038/emm.2001.24 · Cited by 24
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationCombination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
“173 212 Developing immunotherapy-based combination therapies (e.g., CTLA4, PD-1/PD-L1) has emerged as a prominent trend in the fi eld of cancer vaccine application (discussed in the combined therapy section above).”
BackgroundRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 395
“Nearly 43% of patients demonstrated tumor regression, and patients mounted a HPV16-specific T-cell response (192).”
Background
Metadata
- Authors
- Melief, C. J. M., Welters, M. J. P., Vergote, I., Kroep, J. R., Kenter, G. G., Ottevanger, P. B., Tjalma, W. A. A., Denys, H., van Poelgeest, M. I. E., Nijman, H. W., Reyners, A. K. L., Velu, T., Goffin, F., Lalisang, R. I., Loof, N. M., Boekestijn, S., Krebber, W. J., Hooftman, L., Visscher, S., Blumenstein, B. A., Stead, R. B., Gerritsen, W., & van der Burg, S. H.
- Affiliations
- Leiden University Medical Center (NL)
- Universitair Ziekenhuis Leuven (BE)
- Centrum voor Gynaecologische Oncologie Amsterdam (NL)
- Radboud University Medical Center (NL)
- Antwerp University Hospital (BE)
- Ghent University Hospital (BE)
- Department of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.
- University Medical Center Groningen (NL)
- Centre Hospitalier Interrégional Edith Cavell (BE)
- Chirec Cancer Institute, Medical Centre Edith Cavell, Rue Edith Cavell 32, 1180 Brussels, Belgium.
- Maastricht University Medical Centre (NL)
- ISA Pharmaceuticals (Netherlands) (NL)
- Trial Architecture Consulting, 4703 Morgan Dr., Chevy Chase, MD 20815, USA.
- BioPharma Consulting Services, 691 96th Avenue Southeast, Bellevue, WA 98004, USA.
- Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, Netherlands.
- Corresponding author
- Melief, Cornelis J. M.
- Welters, Marij J. P.
- Gerritsen, Winald
- ORCID
- Melief, Cornelis J. M.
- Welters, Marij J. P.
- Vergote, Ignace
- Kroep, Judith R.
- Kenter, Gemma G.
- Ottevanger, Petronella B.
- Tjalma, Wiebren A. A.
- Denys, Hannelore
- Nijman, Hans W.
- Reyners, Anna K. L.
- Velu, Thierry
- Lalisang, Roy I.
- Loof, Nikki M.
- Boekestijn, Sanne
- Visscher, Sonja
- Blumenstein, Brent A.
- Stead, Richard B.
- Gerritsen, Winald
- van der Burg, Sjoerd H.
- Venue
- Science Translational Medicine
- Published
- 2020-03-18
- Volume
- 12
- Issue
- 535
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3012160408
- Cited by
- 134
- References
- 43
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 15 · 2023: 22 · 2022: 25 · 2021: 26 · 2020: 14
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- other-oa
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- dutch cancer society (2009-4400)
- ISA Pharmaceuticals (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- therapeutic cancer vaccines, HPV16, cervical cancer, paclitaxel-carboplatin chemotherapy, chemoimmunotherapy, myeloid-derived suppressor cells, antitumor immunity, vaccine-induced T cell responses, cancer survival
- MeSH terms
- Uterine Cervical Neoplasms, Female, Humans, Cancer Vaccines, Papillomavirus Infections, Papillomavirus E7 Proteins, Human papillomavirus 16, Papillomavirus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.